1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Bioxytran, Inc.
  6. Company
    BIXT   US09075D1028

BIOXYTRAN, INC.

(BIXT)
Delayed OTC Markets  -  05/27 09:30:02 am EDT
0.2600 USD   -27.78%
05/23BIOXYTRAN, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/23Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/11BIOXYTRAN, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
SummaryQuotesChartsNewsCompanyFinancials 
Business Summary
Bioxytran, Inc. is a clinical stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company's subsidiary, Pharmalectin Inc., is focused on the development, manufacturing and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Number of employees : 3 people.
Managers
Name Title Age Since
David Platt, Dr. Chairman & Chief Executive Officer 68 2018
Ola Soderquist Chief Financial Officer, Secretary & Treasurer 60 -
Michael Sheikh Executive Vice President-Business Development 51 -
Members of the board
Name Title Age Since
David Platt, Dr. Chairman & Chief Executive Officer 68 2018
Dale H. Conaway, Dr. Independent Director 66 2018
Alan M. Hoberman, Dr. Independent Director 68 2018
Anders N. Utter Independent Director 54 2018
Hana Chen-Walden, Dr. Independent Director 74 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 110,840,998 24,378,726 22.0% 0 0.0% 22.0%
Shareholders
NameEquities%
David Platt 45,095,837 40.7%
Ola Soderquist 24,127,837 21.8%
Michael Sheikh 9,399,517 8.48%
Binder Offer 8,919,169 8.05%
Alan M. Hoberman 444,100 0.40%
Anders N. Utter 389,900 0.35%
Dale H. Conaway 370,800 0.33%
Hana Chen-Walden 277,800 0.25%
Henry Jemil Esber 3,000 0.0027%
Maple Capital Management, Inc. 833 0.0008%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Bioxytran, Inc.